NO20073490L - Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav - Google Patents

Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav

Info

Publication number
NO20073490L
NO20073490L NO20073490A NO20073490A NO20073490L NO 20073490 L NO20073490 L NO 20073490L NO 20073490 A NO20073490 A NO 20073490A NO 20073490 A NO20073490 A NO 20073490A NO 20073490 L NO20073490 L NO 20073490L
Authority
NO
Norway
Prior art keywords
antibiotic
factors
compositions
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
NO20073490A
Other languages
English (en)
Inventor
Flavia Marinelli
Daniele Losi
Ameriga Lazzarini
Luciano Gastaldo
Gianpaolo Candiani
Ismaela Ciliato
Enrico Selva
Franco Parenti
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of NO20073490L publication Critical patent/NO20073490L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det beskrives en antibiotisk substans av mikrobiell opprinnelse, vilkårlig benevnt antibiotikum 107891 som produseres ved fermentering av Microbispora sp. ATCC PTA-5024, farmasøytisk akseptable salter og sammensetninger derav, og deres anvendelse som et antibakterielt middel som har en inhibitorisk aktivitet versus mottakelige mikrober. Antibiotikum 107891, som er et kompleks som omfatter to faktorer, benevnt faktor Al og faktor A2, har en peptidstruktur som inneholder lantionin og metyllantionin som bestanddeler og som er typiske karakteristika for antibiotika av lantibiotikagruppen. Antibiotikum 107891 og dets faktorer Al og A2 viser en god antibakteriell aktivitet mot Grampositive bakterier inkluderende meticillinresistente og vancomycinresistente stammer, og er også aktiv mot noen Gramnegative bakterier så som M. catharralis, Neisseria-arter og H. influenzae og Mycobacteria.
NO20073490A 2005-01-26 2007-07-05 Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav NO20073490L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/045,628 US7351687B2 (en) 2003-07-18 2005-01-26 Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
PCT/US2005/002733 WO2006080920A1 (en) 2005-01-26 2005-01-27 Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof

Publications (1)

Publication Number Publication Date
NO20073490L true NO20073490L (no) 2007-08-07

Family

ID=36740829

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073490A NO20073490L (no) 2005-01-26 2007-07-05 Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav

Country Status (26)

Country Link
US (1) US7351687B2 (no)
EP (2) EP2402366A1 (no)
JP (1) JP4191238B2 (no)
KR (1) KR100896826B1 (no)
CN (1) CN101189252B (no)
AU (1) AU2005326149C1 (no)
BR (1) BRPI0519942A2 (no)
CA (1) CA2593801A1 (no)
CY (1) CY1113030T1 (no)
DK (1) DK1848731T3 (no)
EA (1) EA016608B1 (no)
ES (1) ES2387557T3 (no)
HR (1) HRP20120634T1 (no)
IL (1) IL184377A0 (no)
MA (1) MA29237B1 (no)
MX (1) MX2007009059A (no)
NO (1) NO20073490L (no)
NZ (1) NZ556368A (no)
PL (1) PL1848731T3 (no)
PT (1) PT1848731E (no)
RS (1) RS52427B (no)
SI (1) SI1848731T1 (no)
TN (1) TNSN07286A1 (no)
UA (1) UA87548C2 (no)
WO (1) WO2006080920A1 (no)
ZA (1) ZA200705495B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
CA2749278A1 (en) 2009-01-14 2010-07-22 Novacta Biosystems Limited Deoxyactagardine derivatives
CN102388060B (zh) 2009-02-04 2014-09-10 诺瓦克塔生物系统有限公司 阿肽加定衍生物
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59198982A (ja) 1983-04-28 1984-11-10 Meiji Seika Kaisha Ltd 新抗生物質ｓｆ−２２４０物質およびその製造法
EP0592835A3 (en) 1992-09-23 1995-03-15 Bristol Myers Squibb Co BU-4803T antibiotics.
US6551591B1 (en) 2001-09-07 2003-04-22 Essential Therapeutics, Inc. Antibiotics from microbispora
US6551581B1 (en) 2001-12-27 2003-04-22 Avon Products, Inc. Methods for improving the aesthetic appearance of skin and hair
ES2281808T3 (es) 2003-07-18 2007-10-01 Vicuron Pharmaceuticals, Inc. Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo.
PT1855705E (pt) * 2005-01-12 2012-10-16 Sentinella Pharmaceuticals Inc Sentinella Antibiótico 107891, seus factores, seus sais aceitáveis sob o ponto de vista farmacêutico e suas composições, e sua utilização
WO2006075988A1 (en) 2005-01-12 2006-07-20 Vicuron Pharmaceuticals Inc. Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof
BRPI0519325A2 (pt) * 2005-01-12 2009-01-13 Vicuron Pharm Inc compostos, complexo antibiàtico 107891, seus fatores a1 e a2, sais farmaceuticamente aceitÁveis, processo para produzir composiÇço e uso do mesmo

Also Published As

Publication number Publication date
JP4191238B2 (ja) 2008-12-03
AU2005326149A1 (en) 2006-08-03
CN101189252A (zh) 2008-05-28
KR20070090043A (ko) 2007-09-04
DK1848731T3 (da) 2012-09-03
EP2402366A1 (en) 2012-01-04
EA016608B1 (ru) 2012-06-29
SI1848731T1 (sl) 2012-09-28
UA87548C2 (ru) 2009-07-27
CY1113030T1 (el) 2016-04-13
EP1848731B1 (en) 2012-05-23
AU2005326149B2 (en) 2009-10-29
IL184377A0 (en) 2007-10-31
ES2387557T3 (es) 2012-09-26
JP2008528581A (ja) 2008-07-31
EP1848731A1 (en) 2007-10-31
US20050233952A1 (en) 2005-10-20
EP1848731A4 (en) 2008-11-12
CA2593801A1 (en) 2006-08-03
AU2005326149C1 (en) 2010-04-01
PL1848731T3 (pl) 2012-10-31
WO2006080920A1 (en) 2006-08-03
RS52427B (sr) 2013-02-28
BRPI0519942A2 (pt) 2009-04-07
CN101189252B (zh) 2012-07-18
HRP20120634T1 (hr) 2012-08-31
US7351687B2 (en) 2008-04-01
EA200701384A1 (ru) 2008-02-28
MX2007009059A (es) 2008-02-12
TNSN07286A1 (fr) 2008-12-31
KR100896826B1 (ko) 2009-05-12
ZA200705495B (en) 2008-12-31
PT1848731E (pt) 2012-08-20
NZ556368A (en) 2010-09-30
MA29237B1 (fr) 2008-02-01

Similar Documents

Publication Publication Date Title
NO20073490L (no) Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav
Römling et al. Biofilm infections, their resilience to therapy and innovative treatment strategies
Giacometti et al. In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics
Wang et al. Antimicrobial compounds from marine actinomycetes
MX2010004407A (es) Antibioticos de carbacefem beta-lactama.
BRPI0513903A (pt) derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
JP2012513467A5 (no)
MXPA06000691A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas.
Selvaraj et al. Statistical optimization of media components for antibiotic production in Streptomyces sp. CMSTAAHAL-3
Gopinath et al. Antimicrobial activity of actinomycetes isolated from coal mine soils of godavari belt region, AP, India
AR073917A1 (es) Sinergismo antibiotico
WO2010030811A3 (en) CARBACEPHEM β-LACTAM ANTIBIOTICS
NO20073491L (no) Antibiotikum 107891, dets faktorer A1 og A2, samt farmasoytisk akseptable salter og sammensetninger, og anvendelser derav
Koyama et al. New structural scaffold 14-membered macrocyclic lactone ring for selective inhibitors of cell wall peptidoglycan biosynthesis in Staphylococcus aureus
NZ599175A (en) Antibiotic compounds
Nastro et al. Antimicrobial activity of Bacillus amyloliquefaciens ANT1 toward pathogenic bacteria and mold: effects on biofilm formation
WO2007127218A3 (en) Streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria
CY1113157T1 (el) Αντιβιοτικο 107891, παραγοντες του, φαρμακευτικως αποδεκτα αλατα και συνθεσεις και η χρηση τους
Darabpour et al. Isolation of an antibiotic producer Pseudomonas sp. from the Persian Gulf
WO2010012381A8 (en) Streptospirole derivatives
NO20042181L (no) Antibiotiske GE 81112-faktorer A, B, B1, farmasoytisk akseptable salter og sammensetninger samt anvendelse derav
MY148891A (en) Novel antibiotic, bispolides a1, a2 and a3, and process for poducing the same
Park et al. Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides
MY149603A (en) Novel antibiotics, bispolides a1, a2, and a3, as well as bispolides b1, b2a, b2b and b3, and process for producing these antibiotics
Churkina et al. Peculiarities of antibiotic batumin action on biofilm formation by Staphylococcus aureus and Pseudomonas batumici

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application